

Logical modelling of myelofibrotic microenvironment predicts dysregulated progenitor stem cell crosstalk

Chapman S. P. ^{1*}, Duprez E. ², and Remy, E. ¹

¹ I2M, Aix-Marseille University, CNRS, Marseille, France

² CRCCM, Aix-Marseille University, CNRS UMR7258, Institut Paoli-Calmettes, Marseille, France

Abstract

Primary myelofibrosis is an untreatable age-related disorder of haematopoiesis in which a break in the crosstalk between progenitor Haematopoietic Stem Cells (HSCs) and neighbouring mesenchymal stem cells causes HSCs to rapidly proliferate and migrate out of the bone marrow. 90% of patients harbour mutations in driver genes that all converge to overactivate hematopoietic JAK-STAT signalling, which is thought to be critical for disease progression, as well as microenvironment modification induced by chronic inflammation. The trigger to the initial event is unknown but dysregulated thrombopoietin (TPO) and Toll-Like Receptor (TLR) signalling are hypothesised to initiate chronic inflammation which then disrupts stem cell crosstalk. Using a systems biology approach, we have constructed an inter and intracellular logical model that captures JAK-STAT signalling and key crosstalk channels between haematopoietic and mesenchymal stem cells. The aim of the model is to decipher how TPO and TLR stimulation can perturb the bone marrow microenvironment and dysregulate stem cell crosstalk. The model predicted conditions in which the disease was averted and established for both wildtype and ectopically JAK mutated simulations. The presence of TPO and TLR are both required to disturb stem cell crosstalk and result in the disease for wildtype. TLR signalling alone was sufficient to perturb the crosstalk and drive

disease progression for JAK mutated simulations. Furthermore, the model predicts the probability of disease onset for wildtype simulations that matches clinical data. These predictions might explain why patients who test negative for the JAK mutation can still be diagnosed with PMF, in which continual exposure to TPO and TLR receptor activation may trigger the initial inflammatory event that perturbs the bone marrow microenvironment and induce disease onset.

Keywords

Logical model, myelofibrosis, haematopoiesis, bone marrow, cell crosstalk

Introduction

Primary myelofibrosis (PMF) is an idiopathic age-related clonal neoplastic disorder of haematopoiesis. Out of all the subsets of myeloproliferative neoplasms (including polycythaemia and essential thrombocytosis), PMF represents the highest morbidity and mortality and mean survival is estimated at less than 6 years post-prognosis (Bartalucci *et al.* 2013; Bartels *et al.* 2020).

More than 90% of myelofibrosis cases harbour somatic mutations in the driver genes JAK, CALR, or MPL that lead to constitutive activation of the JAK-STAT signalling pathways (Coltro *et al.* 2021). Following JAK activation, haematopoietic stem cells (HSCs) become hypersensitive to growth factors, rapidly proliferate and migrate from the bone marrow (BM) to sites of extramedullary haematopoiesis in the liver and spleen (Desterke *et al.* 2015; Hasselbalch. 2013). PMF is also accompanied by an event of

chronic inflammation, which appears to be secondary considering that independent overexpression of each of the driver mutations in mice have been shown to recapitulate distinctive features of human disease mutations leading to JAK overactivity (Rumi *et al.*, 2020).

Research has linked abnormally high levels of TGF β , a potent inflammatory cytokine produced from atypical and dysmorphic megakaryocytes (MK) (Malara *et al.* 2018) in response to disrupted thrombopoietin (TPO) signalling in both patients and mouse models of the disease (Chagraoui *et al.* 2002; Melo-Cardenas *et al.* 2021). TPO, secreted from fibroblasts, is essential for MK differentiation and maintenance of HSCs (Cui *et al.* 2021) and signals through the JAK receptor (Varghese *et al.* 2017).

Current treatment protocols aim to disrupt the overactive STAT pathways (Stark and Darnell Jr. 2012; Pardanani *et al.* 2011) and diminish the effects of chronic inflammation, but are unable to influence the altered BM (Kuykendall *et al.* 2020). Within the BM microenvironment, HSCs reside in an endosteal niche and are engaged in constant crosstalk with neighbouring Mesenchymal Stem Cells (MSCs). MSCs secrete the chemokine CXCL12 and Vascular Cell Adhesion molecule-1 (VCAM1) which bind to their respective receptors, CXCR4 and VLA4, expressed upon the surface of HSCs. (Lubkova *et al.* 2011; Liekens *et al.* 2010). Chronic inflammation is believed to result in a break in any of these communication pathways which leads to HSC migration (Caocci *et al.* 2017).

ligand-activated stimulation of Toll-Like Receptors (TLRs) are well documented to induce chronic inflammation (Desterke *et al.* 2015; Fisher *et al.* 2017; Fisher *et al.* 2019; Fisher *et al.* 2021; Mascarenhas *et al.*, 2022), leading to the hypothesis that unregulated TLR, and/or TPO signalling could be responsible for triggering chronic inflammation. This would then perturb the BM microenvironment and disrupt the crosstalk between HSCs and MSCs and lead to HSC migration and disease development. (Desterke *et al.* 2015). This hypothesis emphasises a major role of the microenvironment in the development of myeloproliferative neoplasms, and is interesting to consider in the context of patients who are “triple-negative” for one of the driver mutations (Tefferi and

Vannucchi 2017), and for the 0.1 – 0.2% of the general population who carry the JAK mutation without showing overt signs of any myeloproliferative neoplasm (Nielsen *et al.* 2014).

It is well known that the presence of feedback circuits (or feedback loops) within biological systems ensures the maintenance of dynamical stability (Cornish-Bowden and Cárdenas. 2008; Qian and Beard. 2006). The idiopathic onset of PMF is believed to arise from an altered microenvironment that perturbs such feedback loops and results in disrupted communication between progenitor stem cells residing within the BM. The challenge of understanding disease onset therefore, requires a thorough understanding of how regulatory circuits control and regulate HSC-MSK crosstalk, and this challenge can be met using a computational systems approach. Construction of a computational model allows for a better understanding of the cause and effect of feedback loops and also provides a tool for making *in silico* predictions.

Quantitative and qualitative mathematical modelling formalisms have become powerful tools to study complex biological systems (Chaouiya *et al.* 2004; Montagud *et al.*, 2019). Logical modelling presents a qualitative approach consisting of modelling regulatory networks using logical statements and allows for qualitative descriptions of dysregulated cellular signalling cascades resulting from altered microenvironments (Albert and Thakar. 2014; Naldi *et al.* 2015; Thieffry. 2007). Within this formalism, interesting insights between network structures and corresponding dynamical properties have been demonstrated (Remy and Ruet. 2008).

Enciso *et al.* (2016) published a logical model focusing on the inflammatory BM environment in response to TLR activation to capture NFK β -dependent inflammation through disruption of the CXCL12/CXCR4 and VLA4/VCAM1 axis, accountable for the onset of Acute Lymphoblastic Leukaemia. We have elaborated upon this existing model to produce an extended model that captures the crosstalk and the key signalling pathways in the BM microenvironment whose alterations may lead to the onset of PMF.

Results

Logical modelling of the bone marrow microenvironment and stem cell crosstalk

A published logical model centred on the haematopoietic microenvironment between the HSC and MSC explaining lymphoblastic leukaemia (Enciso *et al.* 2016) was used as a starting model. This model, which contains 26 nodes and 80 interactions, encompasses the main communication pathways between HSPC and MSC within the BM, namely CXCL12/CXCR4 and VLA4/VCAM1 signalling. Whilst keeping with TLR signalling as an input, we replaced the original connexin43 input with TPO signalling due to its relevance in PMF. We also extended the HSC submodel by including JAK-STAT signalling pathway that is activated by either the TPO ligand or IL6 cytokine (Hasselbalch. 2013; Desterke *et al.* 2015; Fisher *et al.* 2019) which induces downstream PI3K/Akt signalling pathways (DelaRosa and Lombardo. 2010; Kawai and Akira. 2007; Bartalucci *et al.* 2013) and GCSF signalling (Schuettpeitz *et al.* 2014; Brenner and Bruserud. 2019). We also removed the nodes CXCR7 and GFIL1 from the original HSC submodel as these nodes, despite being important in ALL, were considered to play a less important role in the development of PMF. Additionally, we have expanded the initial model by including an MK submodel, along with the main MK signalling pathways that are known to be dysregulated in PMF, that is with JAK-STAT signalling, TGF β and PF4 production. Dysregulations in these pathways have been observed to alter the crosstalk between HSC and MSCs in the context of PMF.

We then set the output of the model as 'PMF' and included two pseudo output nodes, 'HSC_proliferation' and 'HSC_migration' that act as model readouts by concising characteristic cell fates relating to the disease.

A further defining feature of the model is that we have made use of multivalued nodes to discretise node activation states. Multivalued variables were associated with 9 nodes

which allowed the capture of several threshold effects related to those nodes. The JAK, STAT, PI3K/Akt and NFK β nodes of the HSC and MK submodels were given multivalued nodes. This is because 90% of PMF cases observe hyperactive JAK activity, resulting in the overactivation of downstream STAT, PI3K/Akt and NFK β signalling within the HSC submodel (Rumi *et al.* 2006). We were able to capture these threshold effects within the model by allowing STAT, PI3K/Akt and NFK β nodes to take their activity from the respective JAK activity, both in HSC and MK. The remaining node to be given a multivalued threshold was 'HSC_proliferation' which takes its value from HSC PI3K/Akt activity. HSC PI3K/Akt activity of 1 would activate 'HSC_proliferation' at its first, or basal level (considered as normal behaviour for stem cells); whilst HSC PI3K/Akt at its maximum threshold of 2 would then activate 'HSC_proliferation' at its highest level of 2. This second threshold reflects hyperproliferation as a consequence of overactive PI3K/Akt signalling, and this is associated with myeloproliferation (Skoda *et al.* 2015; Fisher *et al.* 2021) which is associated with PMF. In this way, we could set the output of the model as PMF, which is only activated when 'HSC_proliferation' has reached its maximum level of 2, and when 'HSC_migration' and 'TGF β _MK' are activated.

The central axis within this expanded model is the CXCL12/CXCR4 chemokine pathway that now connects the MSC with HSC and MK submodels and plays essential roles in homeostasis and haematopoiesis (Moll and Ransohoff. 2010; Tamura *et al.* 2011). CXCR4 activation increases the affinity between VCAM1 expressed on the surface of MSC and its receptor VLA4, expressed by HSC and MK. Both pathways, CXCL12/CXCR4 and VCAM1/VLA4 are implicated with HSC migration (Lubkova *et al.* 2011; Moll and Ransohoff. 2010), and so the node 'HSC_migration' becomes activated when either the CXCL12/CXCR4 or VCAM1/VLA4 communication axis are broken. Otherwise, communication along these pathways triggers the PI3K/Akt and ERK signalling pathways that govern cellular activity and physiology (Yu and Cui. 2016).

Recent evidence links elevated secretion of pro-inflammatory cytokines within the BM niche in patients with PMF, including IL1 and IL6 (Desterke *et al.* 2015; Hasselbalch. 2013; Skoda *et al.* 2015), PF4 (Gleitz *et al.* 2020; Melo-Cardenas *et al.* 2021) and TGF β

(Agarwal *et al.* 2016; Yao *et al.* 2019). IL1 provides an amplification role with chronic inflammation by activating PI3K/Akt and then NFK β signalling, resulting in elevated production of both IL1, and ROS with the latter being counterbalanced by activation of FOXO transcription factors (Naka *et al.* 2008; Zhang *et al.* 2016). At the mesenchymal counterpart, TGF β being produced by the MK has been reported to inhibit both VCAM1 (Park *et al.* 2000) and CXCL12 (Chagraoui *et al.* 2002), yet upregulates ERK signalling (Xue *et al.* 2020) and these interactions were also captured within the model. The inclusion of GSK3 β and β -catenin in both HSC and MSC sub-models is relevant due to their roles as intermediates of signalling transduction and regulation of the main intracellular communication elements proposed in our network reconstruction (Figure 1).

Modifying and expanding the model (Enciso *et al.* 2016) in order to account for myelofibrotic conditioning of the BM microenvironment (based on evidence in the literature, see Methods), we have obtained an extended model containing 40 nodes and 104 interactions (**Figure 1**).

This model was converted to a dynamical model by associating distinct logical rules to each node specifying the effect of the combination of the incoming interactions, based on biological knowledge. All logical rules and associated references can be found in **Supplementary materials Table S1**.

The model is available in XML format (GINML) on the GINsim Repository (<http://ginsim.org/node/253>).




Figure 1. Regulatory graph capturing the crosstalk between HSC (blue nodes), MSC (dark green nodes), MK (red nodes) and inflammatory cytokines (light green nodes) belonging to the BM microenvironment. Nodes are connected by directed edges representing activations (green) and inhibitions (red). Regardless of sub-model specificity, ellipse-shaped nodes represent boolean nodes whilst rectangle-shaped nodes represent multivalued nodes. All logical rules and associated references can be found in Supplementary Table S1.

The topology of the regulatory graph consists of a unique strongly connected component containing seven positive, and five negative functional circuits (see **Supplementary Table S2**, and **Supplementary Figure S3**). Some of these functional circuits interconnect all the cell submodels (HSC, MSC and MK), through the inflammatory cytokines submodel which implies an important role of inflammatory cytokines associated with disease onset. This emphasises a driving dynamics created by the cellular crosstalk between the several constituents of the BM microenvironment that is altered during the onset of PMF.

(columns) a colour represents its state (see legend). Presence of several colours represent values of oscillating nodes. For example, in the first attractor with all inputs absent (first line), node 'PI3K/Akt_H' oscillates between 0 and 1, and 'PI3K/Akt_MK' is between 1 and 2.

In the absence of both inputs, MSC and HSC submodels remain connected via activation of CXCL12/CXCR4, and VCAM1 binding with VLA4 yet the multivalued 'HSC_proliferation' node oscillates between inactive and a state of partial activation but is never fully activated to its maximum threshold of 2.

The oscillatory range of 'HSC_proliferation' increases with the addition of either, or both inputs. When TPO is introduced as an input it binds to its receptor and combined with IL6, over-activates JAK and STAT signalling within the HSC and MK submodels. These oscillations drive both JAK receptors to now oscillate between the values of 0, 1 and 2, which then allows for a greater oscillatory nature of STAT and PI3K/Akt signalling which activates 'HSC_proliferation'.

The presence of the TLR as a sole input triggers the activation of several positive feedback circuits that impact the HSC, MSC, MK and BM microenvironment. One of these cycles involves the direct activation of NFK β and PI3K/Akt nodes from within the HSC and MK submodels resulting in the activity of 'HSC_migration' to oscillate. This is because TLR stimulates GCSF production which contributes to the inhibition of CXCR4 expression. TLR signalling also activates feedback cycles within the MK submodel that involve PI3K/Akt activation. PI3K/Akt activated at its maximal level results in the production of TGF β from the MK which inhibits CXCL12 expression, yet upregulates PI3K/Akt signalling within the HSC which activates 'HSC_migration'. When 'PI3K/Akt_MK' is inactive or at its basal level of 1, TGF β is inactive and so CXCL12 remains activated and allows communication with the MSC via CXCR4.

When both inputs are introduced we observe oscillations of the 'PMF' output and so this attractor may describe a subset of PMF patients who don't exhibit any driver mutation which may agree with the clinical data (Agarwal *et al.* 2016). In addition, TPO and TLR

activate negative feedback circuits which result in the oscillatory activation of the 'HSC_migration' node. This cyclic attractor represents the communication breakdown of the HSC with the MSC and its migration out of the BM, as a result of TGF β production. It is only in situations where the oscillatory activity of 'HSC_proliferation' is at its maximal level, and when the HSC is migrating, that we see the activation of the output node 'PMF'. On the contrary, the onset of PMF is predicted to be avoided when the oscillatory activity of TGF β remains inactive and when the HSC PI3K/Akt pathway remains in a status that is below its maximal activity. In order to get a finer description of the attractors, we ran stochastic simulations using MaBoSS (see methods). In particular, we wanted to calculate the probability of the 'PMF' output node being activated within the cyclic attractor obtained with both inputs present. As MaBoSS considers only Boolean systems, the multivalued node HSC_proliferation has been duplicated in two Boolean nodes, 'HSC_proliferation_b1' (centred on the threshold 1) and 'HSC_proliferation_b2' (centred on the threshold 2). When [TPO, TLR] = [1, 1], we observe that the nodes 'HSC_migration' and 'HSC_proliferation' follow similar trajectories and both have a 55-60% probability of being activated in this cyclic attractor. The probability of 'HSC_proliferation_b2' node ('HSC_proliferation' at its maximum level of 2) being activated in these conditions was predicted to happen with 17% probability, whilst activation of the 'PMF' output node was predicted to be activated with a probability of 8% which agrees with clinical data that 7-10% of PMF patients test negative for any of the driver mutations that overactive JAK signalling (**Figure 3**).




Figure 3. Probability of output nodes to be activated in the cyclic attractor from MaBoSS WT simulations, with both inputs present. 'HSC_proliferation_b1' represents the node has reached level 1 and 'HSC_proliferation_b2' is when the node has reached level 2.

We also investigated the probability of the oscillatory nodes JAK and TGF β being activated in the cyclic attractor (**Figure 5**). MaBoSS simulations showed an early increase in JAK activity, with the probability of being active at level 1 stabilising at 55% (after a transient peak at 70%). The probability of JAK achieving its level 2 activation is observed to be 30%. Once activated, 'JAK_H' remains activated because of sustained activation of IL6 which overrides the negative cycle involving SOCS inhibition of JAK. TGF β release from MK was estimated to be 55% probable (**Figure 4**).




Figure 4. Probability of select nodes to be activated in the cyclic attractor from MaBoSS WT simulations, in the presence of both inputs. 'JAK_H_b1' represents the node reaching level 1 and 'JAK_H_b2' is when this multivalued node has reached level 2.

When comparing **Figures 3** and **4**, we observe a concomitant activation of HSC migration and proliferation (at level 1) with the progressive increase of IL6 activation and the probability of activating 'JAK_H' at its highest level is also increasing. This might explain the increase in probable activation of HSC overproliferation ('HSC_proliferation_b2'). Meanwhile, the probability of TGF β release increases, which explains the increasing probability of activating PMF.

To conclude, these simulations reveal that in the absence of the JAK mutation (WT situation), both inputs TPO and TLR have to be present for PMF to be activated, probably arising from a JAK overactivation which cascades inflammatory feedback circuits through IL6 and TGF β pathways.

not predicted to migrate because of a sustained connection with the MSC submodel following the activation of mesenchymal PI3K/Akt which promotes the activation of VCAM1 and allows the reception of VLA4. Furthermore, TGF β and GCSF are inactive and so CXCL12/CXCR4 remain active in the absence of TLR. This could explain why the subset of the population who exhibit any driver mutation that overactivates the JAK receptor avoids the onset of PMF.

Following activation of both inputs for JAK mutated simulations, TLR signalling augments the JAK burden in the MK submodel causing overactivation of PI3K/Akt signalling and this time, NFK β signalling. TPO also augments JAK stimulation, and TLR activates GCSF and PF4, and inactivates CXCR4 and VLA4, resulting in the loss of communication between the HSC and MSC submodels. Hyperactive JAK signalling within the HSC submodel led to overactive PI3K/Akt, and when combined with the activation of 'HSC_migration' and TGF β , led to the activation of the output node 'PMF', at a calculated probability of 100% (**Supplementary materials Figure S4**).

Again, these results agree with the literature that shows activation of TPO and JAK are both required to induce a myelofibrotic phenotype (Besancenot *et al.* 2014). Furthermore, PF4 (Gleitz *et al.* 2020) and TGF β (Chagraoui *et al.* 2002; Zingariello *et al.* 2013; Agarwal *et al.* 2016) are critically implicated with disease progression. In conclusion, JAK (KI) mutated simulations predict that TLR signalling is sufficient to perturb the microenvironment and disrupt HSC-MSC crosstalk to drive disease onset.

Discussion and Conclusion

Primary myelofibrosis is an untreatable age-related disorder of haematopoiesis in which a break in the crosstalk between progenitor HSCs and neighbouring mesenchymal stem cells (MSC) caused HSCs to rapidly proliferate and migrate out of the bone marrow. In this work, we have elaborated and adapted a pre-existing logical model of lymphoblastic leukaemia (Encisco *et al.*, 2016) to account for the BM microenvironment with the primary aim of capturing stem cell cross-talk between HSC, MSC and megakaryocyte

progenitors. We then used the model to capture the dysregulation of the cell crosstalk following perturbation of the BM microenvironment due to stimulation with TPO, and/or activation of TLR, for wildtype and in ectopically JAK mutated situations. We chose to include TPO and TLR signalling as inputs due to their roles in mediating chronic inflammation.

The model predicted that for wildtype scenarios, the presence of both inputs (TPO and TLR) resulted in a probability of disease. TLR signalling was predicted to activate PF4, which agrees with (Gleitz *et al.* 2020) who report that elevated expression of PF4 links inflammation with progression of BM fibrosis. The authors also report that the absence of PF4 reduces the extent of BM remodelling in presence of overactive JAK pathways, which our model has qualitatively captured (**Figure 2; Figure 5**). Our results suggest that TLR signalling cascades positive and negative feedback circuits that are responsible for triggering an initial event of chronic inflammation through the activation of PF4 and TGF β . TPO signalling cascaded further positive and negative feedback circuits that facilitate HSC hyperproliferation, independent of the JAK mutation. These predictions might explain why patients who test negative for the JAK mutation can still be diagnosed with PMF, in which continual exposure to TPO and TLR receptor activation may trigger the onset of PMF. JAK mutated (KI) simulations revealed that TLR alone was sufficient to drive myelofibrosis. The model also predicted that in the presence of JAK mutation and absence of TLR, PMF was averted which supports the observation that 0.1 – 0.2% of the general population harbour the JAK mutation without showing overt signs of any myeloproliferative disease (**Figure 5**). We hypothesise that the probability of TLR and TPO signalling increases with time, explaining why the onset of PMF is age-related.

Mathematical modelling aims at abstracting and understanding the effects of biological perturbations to suggest ways to intervene and reestablish homeostasis. This is challenging to achieve within any modelling framework. The model presented in this work contains limited, but sufficient biological interactions that play a role in the onset of PMF. We sought to capture as much information as possible while maintaining enough

abstraction to obtain a manageable model of reasonable size for the analysis to be performed. This has allowed the construction of a model that agrees qualitatively -and in some respects even quantitatively- with experimental and clinical data. As a limitation, we are modelling crosstalk between single cells, while in reality, multiple cells reside within a niche which our approach does not take into account. It is therefore essential to explore the dynamics at the scale of interacting cell populations, taking into account their response, death and interactions. This requires a proper computational description of heterogeneous interacting cell populations, and this model could be the basis of such modelling at the cell population level microenvironment.

In conclusion, we have built an intra- and intercellular logical model that is able to capture the crosstalk between distinct progenitor stem cells within the BM microenvironment. The model is able to predict and explain the onset of myelofibrosis for JAK-positive and JAK-negative cases. More generally, this model could be useful for the study of other haematopoietic diseases.

Methods

Logical Modelling

Logical modelling is a qualitative formalism developed to study the dynamics of complex biological networks (Albert and Thakar. 2014; Abou-Jaoudé *et al.* 2016). Biological information is extracted from the literature and/or experiments and abstracted into a regulatory graph (RG), a directed signed graph whose nodes represent selected biological species, connected by regulatory edges (positive edges for activations, negative for inhibitions). Input nodes (nodes with only outgoing interactions) usually represent the environment of the cell or any extracellular signal, and output nodes (that only have incoming interactions and thus no impact on the model) usually serve as a readout of the model. Outputs can reflect an observed phenotype such as ‘proliferation’ and/or ‘migration’, as examples.

To introduce the dynamics, each node is associated with a discrete variable, denoting its state (in the binary case, 0 (inactive) or 1 (active)). Nodes can also be assigned with multivalued values that precise different thresholds, or activation levels. The global state of the network is represented by a vector of n elements, where n represents the number of nodes in the network. Each node is associated with logical rules that describe the target value of the variable with respect to the state of the regulators of the node. These logical rules set the dynamics and the asynchronous updating strategy provides non-deterministic dynamics by updating a single component at each step (see example; Figure 7). Trajectories ultimately end within an attractor, i.e. terminal strongly connected component of the graph and represent the asymptotic behaviours of the system. They can either be fixed points (attractors of size one), or cyclical attractors.

Simulations of mutants consist in modifying logical rules. Knock-out (KO) mutants are simulated by blocking the logical rule of the desired node to 0, and Knock-in (KI) mutants by fixing it to its maximal level or active at the desired threshold for multivalued nodes (overexpression).




Figure 7. Toy model illustrating the logical modelling methodology. The first row depicts a wildtype (WT) situation, and the bottom row depicts a KO mutation of node C. **A)** The regulatory graph (RG) consists of 3 nodes, A, B and C, and 6 edges, 5 activatory edges (green arrows) and one inhibitory edge (the red arrow). **B)** Logical rules (*indicates possible future active state when the following logical rules are met). When node C has

been knocked out (mutant version), its rule is blocked to 0. **C**) Asynchronous State Transition Graphs (STG). The asynchronous STG contains two attractors, a single fixed point $[ABC] = [011]$ (coloured blue) and a cyclic attractor composed of the states $\{[000]; [100]; [110]; [010]\}$ (coloured green). Asynchronous dynamics of the mutant C KO loses the fixed point and only results in the same cyclic attractor (coloured green).

The logical model was built using GINsim software and is available in XML format (GINML) on the GINsim Repository (<http://ginsim.org/node/253>, also provided in Supplementary File 1). All attractors, belonging to either the wildtype and mutant simulations (double mutation JAK_H KI and JAK_MK KI) were sought and characterised using GINsim in conjunction with the CoLoMoTo toolbox (Levy *et al.* 2018) using Python.

Feedback Circuit Analysis

Feedback circuits are known to play a major role in the control of cell signalling dynamics. For instance, the Thomas' rules state that the presence of positive (resp. negative) circuits are necessary prerequisites to generate multistability (resp. sustained oscillations) (Thomas. 1981; Thieffry. 2007).

When embedded within a RG, a circuit is regulated by some external nodes and thereby its activity is affected. Circuit functionality contexts indicate the part of the space in which the positive (resp. negative) circuit is able to generate local multistability (resp. oscillations), and we say that the circuit is functional. These contexts are defined in terms of constraints on the values of external nodes. The “Analyse circuits” tool of GINsim lists all the functional circuits present in a logical model and their context of functionality.

MaBoSS Simulations

MaBoSS (Markovian Boolean Stochastic Simulator; Stoll *et al.* 2017) provides an environment for simulating continuous/discrete time Markov processes based on logical networks by applying the Gillespie algorithm. MaBoSS calculates the time evolution of the probability of node states being activated and so was used to see if the model could predict the probable onset of PMF with, and without JAK mutation as a means of model validation. In addition, global and semi-global characterizations of the whole system are computed. Simulation parameters involve running 50,000 simulations performed to compute statistics and the maximum time representing the duration of the trajectory was set to 30. For wildtype (JAK KO) simulations, the initial states of all nodes were set to zero, apart from the inputs; which were both set to be 100% active. The inputs for the JAK mutated simulations account for TLR which was 100% probable of being activated. The initial states of non-input nodes were then set to inactive apart from 'JAK_MK' and 'JAK_HSC', as these were ectopically mutated to their maximum levels. The average temporal evolution of selected nodes of the model were then plotted.

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Data availability

The data underlying this article are available within the GINsim repository at

<http://ginsim.org/node/253>

Competing interests

The authors declare that they have no competing interests

Funding

ED laboratory is supported by the Ligue Nationale Contre le Cancer, This work has been supported by the the Fondation A*MIDEX.

Authors contributions

ED thought up and designed this work. ER supervised the modelling methodology. SC built, ran and analysed the model and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank A. Naldi for his assistance with GINsim, P. Monteiro for uploading the model to the GINsim model repository, F. Zaccagnino for assisting with MaBoSS and B. Habermann for proofreading the manuscript.

References

Abou-Jaoudé W, Traynard P, Monteiro PT, Saez-Rodriguez J, Helikar T, Thieffry D, Chaouiya C. Logical modeling and dynamical analysis of cellular networks. *Frontiers in genetics*. 2016 May 31;7:94.

Agarwal A, Morrone K, Bartenstein M, Zhao ZJ, Verma A, Goel S. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF- β . *Stem cell investigation*. 2016;3.

Albert R, Thakar J. Boolean modeling: a logic-based dynamic approach for understanding signaling and regulatory networks and for making useful predictions. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*. 2014 Sep;6(5):353-69.

Bartalucci N, Guglielmelli P, Vannucchi AM. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. *Clinical Lymphoma Myeloma and Leukemia*. 2013 Sep 1;13:S307-9.

Bartels S, Faisal M, Büsche G, Schlue J, Hasemeier B, Schipper E, Vogtmann J, Westphal L, Lehmann U, Kreipe H. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. *Leukemia*. 2020 May;34(5):1364-72.

Besancenot R, Roos-Weil D, Tonetti C, Abdelouahab H, Lacout C, Pasquier F, Willekens C, Rameau P, Lecluse Y, Micol JB, Constantinescu SN. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. *Blood, The Journal of the American Society of Hematology*. 2014 Sep 25;124(13):2104-15.

Brenner AK, Bruserud Ø. Functional toll-like receptors (TLRs) are expressed by a majority of primary human acute myeloid leukemia cells and inducibility of the TLR signaling pathway is associated with a more favorable phenotype. *Cancers*. 2019 Jul 11;11(7):973.

Caocci, G., Greco, M., & La Nasa, G. (2017). Bone marrow homing and engraftment defects of human hematopoietic stem and progenitor cells. *Mediterranean journal of hematology and infectious diseases*, 9(1).

Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF- β 1 in thrombopoietin-induced myelofibrosis in mice. *Blood, The Journal of the American Society of Hematology*. 2002 Nov 15;100(10):3495-503.

Chaouiya, C., Remy, E., Ruet, P., & Thieffry, D. (2004, June). Qualitative modelling of genetic networks: From logical regulatory graphs to standard petri nets. In *International Conference on Application and Theory of Petri Nets* (pp. 137-156). Springer, Berlin, Heidelberg.

Coltro G, Loscocco GG, Vannucchi AM. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. *International Review of Cell and Molecular Biology*. 2021 Jan 1;365:1-69.

Cornish-Bowden A, Cárdenas ML. Self-organization at the origin of life. *Journal of theoretical biology*. 2008 Jun 7;252(3):411-8.

Cui L, Moraga I, Lerbs T, Van Neste C, Wilmes S, Tsutsumi N, Trotman-Grant AC, Gakovic M, Andrews S, Gotlib J, Darmanis S. Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia

progenitors. *Proceedings of the National Academy of Sciences*. 2021 Jan 12;118(2):e2017849118.

DelaRosa O, Lombardo E. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. *Mediators of inflammation*. 2010 Oct;2010.

Desterke C, Martinaud C, Ruzehaji N, Bousse-Kerdilès L. Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis. *Mediators of inflammation*. 2015 Oct;2015.

Enciso, J., Mayani, H., Mendoza, L., & Pelayo, R. (2016). Modeling the pro-inflammatory tumor microenvironment in acute lymphoblastic leukemia predicts a breakdown of hematopoietic-mesenchymal communication networks. *Frontiers in physiology*, 7, 349.

Fisher DA, Miner C, Engle E, Collins TB, Hu H, Malkova O, Oh S. Mass Cytometry Analysis Reveals Cellular Loci of Cytokine Overproduction in Myelofibrosis with Differential Sensitivity to Ruxolitinib. *Blood*. 2017 Dec 8;130:4209.

Fisher DA, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, Allen MJ, Malkova ON, Oh ST. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. *Leukemia*. 2019 Aug;33(8):1978-95.

Fisher DA, Fowles JS, Zhou A, Oh ST. Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. *Frontiers in immunology*. 2021 Jun 1;12:2034.

Gleitz HF, Dugourd AJ, Leimkühler NB, Snoeren IA, Fuchs SN, Menzel S, Ziegler S, Kröger N, Trivai I, Büsche G, Kreipe H. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. *Blood*. 2020 Oct 29;136(18):2051-64.

Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. *Cytokine & growth factor reviews*. 2013 Apr 1;24(2):133-45.

Kawai T, Akira S. Signaling to NF-κB by Toll-like receptors. *Trends in molecular medicine*. 2007 Nov 1;13(11):460-9.

Kuykendall AT, Horvat NP, Pandey G, Komrokji R, Reuther GW. Finding a Jill for JAK: assessing past, present, and future JAK inhibitor combination approaches in myelofibrosis. *Cancers*. 2020 Aug 14;12(8):2278.

Levy N, Naldi A, Hernandez C, Stoll G, Thieffry D, Zinovyev A, Calzone L, Paulevé L. Prediction of mutations to control pathways enabling tumor cell invasion with the CoLoMoTo interactive notebook (tutorial). *Frontiers in physiology*. 2018 Jul 6;9:787.

Liekens S, Schols D, Hatse S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. *Current pharmaceutical design*. 2010 Dec 1;16(35):3903-20.

Lubkova ON, Tzvetaeva NV, Momotyuk KS, Belkin VM, Manakova TE. VCAM-1 expression on bone marrow stromal cells from patients with myelodysplastic syndromes. *Bulletin of experimental biology and medicine*. 2011 May;151(1):13-5.

Malara A, Abbonante V, Zingariello M, Migliaccio A, Balduini A. Megakaryocyte contribution to bone marrow fibrosis: many arrows in the quiver. *Mediterranean Journal of Hematology and Infectious Diseases*. 2018;10(1).

Mascarenhas, J., Gleitz, H. F., Chifotides, H. T., Harrison, C. N., Verstovsek, S., Vannucchi, A. M., ... & List, A. F. (2022). Biological drivers of clinical phenotype in myelofibrosis. *Leukemia*, 1-10.

Melo-Cardenas J, Migliaccio AR, Crispino JD. The role of megakaryocytes in myelofibrosis. *Hematology/Oncology Clinics*. 2021 Apr 1;35(2):191-203.

Montagud, A., Traynard, P., Martignetti, L., Bonnet, E., Barillot, E., Zinovyev, A., & Calzone, L. (2019). Conceptual and computational framework for logical modelling of biological networks deregulated in diseases. *Briefings in bioinformatics*, 20(4), 1238-1249.

Moll, N. M., & Ransohoff, R. M. (2010). CXCL12 and CXCR4 in bone marrow physiology. *Expert review of hematology*, 3(3), 315-322.

Naka K, Muraguchi T, Hoshii T, Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. *Antioxidants & redox signaling*. 2008 Nov 1;10(11):1883-94.

Naldi A, Monteiro PT, Müssel C, Consortium for Logical Models and Tools, Kestler HA, Thieffry D, Xenarios I, Saez-Rodriguez J, Helikar T, Chaouiya C. Cooperative development of logical modelling standards and tools with CoLoMoTo. *Bioinformatics*. 2015 Apr 1;31(7):1154-9.

Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. *haematologica*. 2014 Sep;99(9):1448.

Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. *Leukemia*. 2011 Feb;25(2):218-25.

Park SK, Yang WS, Lee SK, Ahn H, Park JS, Hwang O, Lee JD. TGF- β 1 down-regulates inflammatory cytokine-induced VCAM-1 expression in cultured human glomerular endothelial cells. *Nephrology Dialysis Transplantation*. 2000 May 1;15(5):596-604.

Qian H, Beard DA. Metabolic futile cycles and their functions: a systems analysis of energy and control. *IEE Proceedings-Systems Biology*. 2006 Jul 1;153(4):192-200.

Remy E, Ruet P. From minimal signed circuits to the dynamics of Boolean regulatory networks. *Bioinformatics*. 2008 Aug 15;24(16):i220-6.

Rumi E, Passamonti F, Pietra D, Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, Cazzola M. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. *Cancer: Interdisciplinary International Journal of the American Cancer Society*. 2006 Nov 1;107(9):2206-11.

Rumi, E., Trotti, C., Vanni, D., Casetti, I. C., Pietra, D., & Sant'Antonio, E. (2020). The genetic basis of primary myelofibrosis and its clinical relevance. *International Journal of Molecular Sciences*, 21(23), 8885.

Schuettpelz LG, Borgerding JN, Christopher MJ, Gopalan PK, Romine MP, Herman AC, Woloszynek JR, Greenbaum AM, Link DC. G-CSF regulates hematopoietic stem cell activity, in part, through activation of Toll-like receptor signaling. *Leukemia*. 2014 Sep;28(9):1851-60.

Skoda, R.C., Duek, A. and Grisouard, J., 2015. Pathogenesis of myeloproliferative neoplasms. *Experimental hematology*, 43(8), pp.599-608.

Stark GR, Darnell Jr JE. The JAK-STAT pathway at twenty. *Immunity*. 2012 Apr 20;36(4):503-14.

Stoll G, Caron B, Viara E, Dugourd A, Zinovyev A, Naldi A, Kroemer G, Barillot E, Calzone L. MaBoSS 2.0: an environment for stochastic Boolean modeling. *Bioinformatics*. 2017 Jul 15;33(14):2226-8.

Tamura M, Sato MM, Nashimoto M. Regulation of CXCL12 expression by canonical Wnt signaling in bone marrow stromal cells. *The international journal of biochemistry & cell biology*. 2011 May 1;43(5):760-7.

Tefferi A, Vannucchi AM. Genetic risk assessment in myeloproliferative neoplasms. *In Mayo Clinic Proceedings* 2017 Aug 1 (Vol. 92, No. 8, pp. 1283-1290). Elsevier.

Thieffry D. Dynamical roles of biological regulatory circuits. *Briefings in bioinformatics*. 2007 Jul 1;8(4):220-5.

Thomas R. On the relation between the logical structure of systems and their ability to generate multiple steady states or sustained oscillations. *In Numerical methods in the study of critical phenomena* 1981 (pp. 180-193). Springer, Berlin, Heidelberg.

Varghese LN, Defour JP, Pecquet C, Constantinescu SN. The thrombopoietin receptor: structural basis of traffic and activation by ligand, mutations, agonists, and mutated calreticulin. *Frontiers in endocrinology*. 2017 Mar 31;8:59.

Xue VW, Chung JY, Córdoba CA, Cheung AH, Kang W, Lam EW, Leung KT, To KF, Lan HY, Tang PM. Transforming growth factor- β : a multifunctional regulator of cancer immunity. *Cancers*. 2020 Oct 23;12(11):3099.

Yao JC, Abou Ezzi G, Krambs JR, Uttarwar S, Duncavage EJ, Link DC. TGF- β Signaling Contributes to Myelofibrosis and Clonal Dominance of Myeloproliferative Neoplasms. *Blood*. 2019 Nov 13;134:470.

Yu JS, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. *Development*. 2016 Sep 1;143(17):3050-60.

Zhang J, Wang X, Vikash V, Ye Q, Wu D, Liu Y, Dong W. ROS and ROS-mediated cellular signaling. *Oxidative medicine and cellular longevity*. 2016 Oct;2016.

Zingariello M, Martelli F, Ciaffoni F, Masiello F, Ghinassi B, D'Amore E, Massa M, Barosi G, Sancillo L, Li X, Goldberg JD. Characterization of the TGF- β 1 signaling abnormalities in the Gata1^{low} mouse model of myelofibrosis. *Blood, The Journal of the American Society of Hematology*. 2013 Apr 25;121(17):3345-63.